These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

677 related items for PubMed ID: 24521819

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer.
    Ou W, Sun HB, Ye X, Zhang BB, Yang H, Fang Q, Li P, Wang SY.
    J Thorac Oncol; 2010 Jul; 5(7):1033-41. PubMed ID: 20502361
    [Abstract] [Full Text] [Related]

  • 3. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
    Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR.
    J Clin Oncol; 2008 Nov 01; 26(31):5043-51. PubMed ID: 18809614
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial.
    Bennouna J, Senellart H, Hiret S, Vaissiere N, Douillard JY.
    Lung Cancer; 2011 Oct 01; 74(1):30-4. PubMed ID: 21371774
    [Abstract] [Full Text] [Related]

  • 7. Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment.
    Ramsden K, Laskin J, Ho C.
    Clin Oncol (R Coll Radiol); 2015 Jul 01; 27(7):394-400. PubMed ID: 25800720
    [Abstract] [Full Text] [Related]

  • 8. Long term follow-up of neoadjuvant-adjuvant combination treatment of IIIA stage non-small-cell-lung cancer: results of neoadjuvant carboplatin/vinorelbine and carboplatin/paclitaxel regimens combined with selective adjuvant chemotherapy according to in-vitro chemoresistance test.
    Kolek V, Grygarkova I, Hajduch M, Klein J, Cwiertka K, Neoral C, Langova K, Mihal V.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Dec 01; 152(2):259-66. PubMed ID: 19219217
    [Abstract] [Full Text] [Related]

  • 9. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP, Fossella F.
    Cancer; 2005 Dec 15; 104(12):2766-74. PubMed ID: 16288485
    [Abstract] [Full Text] [Related]

  • 10. Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small-cell lung cancer.
    Sun HB, Ou W, Li Y, Fang Q, Qin J, Zhang L, Wang SY.
    Clin Lung Cancer; 2013 Jul 15; 14(4):376-82. PubMed ID: 23291256
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S, Bier A, Thierbach U, Virchow C, Ketterer P, Fietkau R.
    Strahlenther Onkol; 2003 Dec 15; 179(12):823-31. PubMed ID: 14652671
    [Abstract] [Full Text] [Related]

  • 13. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
    Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR.
    J Clin Oncol; 2001 Jul 01; 19(13):3210-8. PubMed ID: 11432888
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.
    Takayama K, Inoue K, Tokunaga S, Matsumoto T, Oshima T, Kawasaki M, Imanaga T, Kuba M, Takeshita M, Harada T, Shioyama Y, Nakanishi Y.
    Cancer Chemother Pharmacol; 2013 Dec 01; 72(6):1353-9. PubMed ID: 24166107
    [Abstract] [Full Text] [Related]

  • 15. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
    Rusu P, Ciuleanu TE, Cernea D, Pelau D, Gaal V, Cebotaru C, Guttman T, Todor N, Ghilezan N.
    J BUON; 2007 Dec 01; 12(1):33-9. PubMed ID: 17436399
    [Abstract] [Full Text] [Related]

  • 16. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
    Lena MD, Ramlau R, Hansen O, Lorusso V, Wagner L, Barni S, Cristovao MM, Huber R, Alberola V, Mitrovic M, Colin C, Gasmi J.
    Lung Cancer; 2005 Apr 01; 48(1):129-35. PubMed ID: 15777980
    [Abstract] [Full Text] [Related]

  • 17. A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.
    Schmid-Bindert G, Engel-Riedel W, Reck M, Schuette W, Stöhlmacher J, Fischer JR, Mazières J, Chouaid C, Wolf M, Vinolas N, Soldatenkova V, Ripoche V, Nguyen T, Visseren-Grul C.
    Lung Cancer; 2015 Dec 01; 90(3):397-404. PubMed ID: 26791798
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M, Macha HN, Del Barco S, Cornes P, Vaissière N, Morand M, Riggi M, Abratt R.
    Lung Cancer; 2009 Jun 01; 64(3):319-25. PubMed ID: 19095327
    [Abstract] [Full Text] [Related]

  • 19. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
    Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF.
    J Clin Oncol; 2012 Jun 10; 30(17):2055-62. PubMed ID: 22547591
    [Abstract] [Full Text] [Related]

  • 20. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH, Gootenberg J, Keegan P, Pazdur R.
    Oncologist; 2007 Jun 10; 12(6):713-8. PubMed ID: 17602060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.